|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CBWD1 |
Gene summary for CBWD1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CBWD1 | Gene ID | 55871 |
| Gene name | COBW domain containing 1 | |
| Gene Alias | COBP | |
| Cytomap | 9p24.3 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q9BRT8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55871 | CBWD1 | HTA11_1938_2000001011 | Human | Colorectum | AD | 6.88e-03 | 3.33e-01 | -0.0811 |
| 55871 | CBWD1 | HTA11_347_2000001011 | Human | Colorectum | AD | 3.38e-03 | 2.73e-01 | -0.1954 |
| 55871 | CBWD1 | HTA11_1391_2000001011 | Human | Colorectum | AD | 1.48e-02 | 2.87e-01 | -0.059 |
| 55871 | CBWD1 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 5.96e-03 | 2.74e-01 | 0.294 |
| 55871 | CBWD1 | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 2.80e-03 | 9.05e-01 | 0.3487 |
| 55871 | CBWD1 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 1.14e-12 | 7.36e-01 | 0.281 |
| 55871 | CBWD1 | A015-C-104 | Human | Colorectum | FAP | 9.89e-04 | -3.39e-02 | -0.1899 |
| 55871 | CBWD1 | LZE2T | Human | Esophagus | ESCC | 2.95e-02 | 5.10e-01 | 0.082 |
| 55871 | CBWD1 | LZE4T | Human | Esophagus | ESCC | 1.51e-15 | 4.67e-01 | 0.0811 |
| 55871 | CBWD1 | LZE5T | Human | Esophagus | ESCC | 1.76e-06 | 4.89e-01 | 0.0514 |
| 55871 | CBWD1 | LZE7T | Human | Esophagus | ESCC | 1.33e-06 | 4.48e-01 | 0.0667 |
| 55871 | CBWD1 | LZE8T | Human | Esophagus | ESCC | 1.89e-05 | 2.01e-01 | 0.067 |
| 55871 | CBWD1 | LZE24T | Human | Esophagus | ESCC | 8.73e-07 | 6.73e-02 | 0.0596 |
| 55871 | CBWD1 | LZE21T | Human | Esophagus | ESCC | 5.82e-08 | 5.74e-01 | 0.0655 |
| 55871 | CBWD1 | LZE6T | Human | Esophagus | ESCC | 4.84e-06 | 4.77e-01 | 0.0845 |
| 55871 | CBWD1 | P2T-E | Human | Esophagus | ESCC | 1.61e-05 | -9.86e-03 | 0.1177 |
| 55871 | CBWD1 | P4T-E | Human | Esophagus | ESCC | 5.97e-27 | 7.65e-01 | 0.1323 |
| 55871 | CBWD1 | P5T-E | Human | Esophagus | ESCC | 1.99e-16 | 4.53e-01 | 0.1327 |
| 55871 | CBWD1 | P8T-E | Human | Esophagus | ESCC | 7.29e-22 | 5.73e-01 | 0.0889 |
| 55871 | CBWD1 | P9T-E | Human | Esophagus | ESCC | 2.30e-18 | 7.02e-01 | 0.1131 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CBWD1 | SNV | Missense_Mutation | c.541N>C | p.Glu181Gln | p.E181Q | Q9BRT8 | protein_coding | tolerated(0.05) | benign(0.417) | TCGA-BH-A18U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| CBWD1 | SNV | Missense_Mutation | novel | c.1168G>A | p.Glu390Lys | p.E390K | Q9BRT8 | protein_coding | tolerated_low_confidence(0.13) | benign(0.073) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| CBWD1 | SNV | Missense_Mutation | novel | c.311G>A | p.Arg104Lys | p.R104K | Q9BRT8 | protein_coding | tolerated(0.51) | possibly_damaging(0.626) | TCGA-VS-A8EI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| CBWD1 | SNV | Missense_Mutation | novel | c.836N>C | p.Phe279Ser | p.F279S | Q9BRT8 | protein_coding | deleterious(0.04) | possibly_damaging(0.516) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| CBWD1 | SNV | Missense_Mutation | novel | c.56N>A | p.Cys19Tyr | p.C19Y | Q9BRT8 | protein_coding | deleterious(0) | possibly_damaging(0.605) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
| CBWD1 | SNV | Missense_Mutation | c.363N>T | p.Glu121Asp | p.E121D | Q9BRT8 | protein_coding | deleterious(0) | probably_damaging(0.936) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
| CBWD1 | SNV | Missense_Mutation | novel | c.749N>A | p.Ser250Asn | p.S250N | Q9BRT8 | protein_coding | tolerated(0.14) | benign(0.011) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CBWD1 | SNV | Missense_Mutation | novel | c.793G>A | p.Gly265Arg | p.G265R | Q9BRT8 | protein_coding | tolerated(0.23) | benign(0.024) | TCGA-EO-A3KX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CBWD1 | SNV | Missense_Mutation | novel | c.892C>A | p.Leu298Met | p.L298M | Q9BRT8 | protein_coding | deleterious(0) | probably_damaging(0.977) | TCGA-EY-A1GU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CBWD1 | SNV | Missense_Mutation | novel | c.890N>C | p.Leu297Pro | p.L297P | Q9BRT8 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-EY-A215-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |